Quality of life and symptoms in male breast cancer survivors

Breast

Volumn 22, Issue 2, 2013, Pages 197-199

  Ruddy, Kathryn J ^a   Giobbie Hurder, Anita ^a   Giordano, Sharon H ^b   Goldfarb, Shari ^c   Kereakoglow, Sandra ^a   Winer, Eric P ^a   Partridge, Ann H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast neoplasms; Hot flashes; Male; Physiologic; Quality of life; Sexual dysfunction; Survivors

Indexed keywords

AROMATASE INHIBITOR; GONADORELIN AGONIST; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVOR; CLINICAL ARTICLE; DEMOGRAPHY; EXPANDED PROSTATE CANCER INDEX COMPOSITE HORMONAL SEXUAL SCALES; FUNCTIONAL ASSESSMENT OF CANCER THERAPY BREAST; HEALTH SURVEY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INTERNET; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SOCIAL ASPECT; SYMPTOM;

EID: 84875526672     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.12.014     Document Type: Article

References (21)

1. Parker P.A., Youssef A., Walker S., Bassen-Engquist K., Cohen L., Gritz E.R., et al. Short-term and long-term psychosocial adjustment and quality of life in women undergoing different surgical procedures for breast cancer. Ann Surg Oncol 2007, 14:3078-3089.
2. Kiebert G.M., de Haes J.C., van de Velde C.J. The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol 1991, 9:1059-1070.
3. Cella D., Fallowfield L., Barker P., Cuzick J., Locker G., Howell A. Quality of life of postmenopausal women in the ATAC (" Arimidex" , tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006, 100:273-284.
4. Partridge A.H., Burstein H.J., Winer E.P. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001, 135-142.
5. Burgess C., Cornelius V., Love S., Graham J., Richards M., Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005, 330:702.
6. Hassett M.J., O'Malley A.J., Keating N.L. Factors influencing changes in employment among women with newly diagnosed breast cancer. Cancer 2009, 115:2775-2782.
7. Fergus K.D., Gray R.E. Relationship vulnerabilities during breast cancer: patient and partner perspectives. Psychooncology 2009, 18:1311-1322.
8. Leining M.G., Gelber S., Rosenberg R., Przypyszny M., Winer E.P., Partridge A.H. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006, 17:1777-1782.
9. Ruddy K.J., Gelber S., Ginsburg E.S., Schapira L., Abusief M.E., Meyer M.E., et al. Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors: a comparison to age- and gravidity-matched controls. Menopause 2011, 18:105-108.
10. Wei J.T., Dunn R.L., Litwin M.S., Sandler H.M., Sanda M.G. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905.
11. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
12. Brady M.J., Cella D.F., Mo F., Bonomi A.E., Tulsky D.S., Lloyd S.R., et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997, 15:974-986.
13. Kimmick G.G., Lovato J., McQuellon R., Robinson E., Muss H.B. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006, 12:114-122.
14. Anelli T.F., Anelli A., Tran K.N., Lebwohl D.E., Borgen P.I. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994, 74:74-77.
15. Visram H., Kanji F., Dent S.F. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 2010, 17:17-21.
16. Pemmaraju N., Munsell M.F., Hortobagyi G.N., Giordano S.H. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol 2012, 23:1471-1474.
17. Wei J.T., Dunn R.L., Sandler H.M., McLaughlin P.W., Montie J.E., Litwin M.S., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002, 20:557-566.
18. de Bock G.H., Bonnema J., Zwaan R.E., van de Velde C.J., Kievit J., Stiggelbout A.M. Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer 2004, 90:1144-1150.
19. Kowalski C., Steffen P., Ernstmann N., Wuerstlein R., Harbeck N., Pfaff H. Health-related quality of life in male breast cancer patients. Breast Cancer Res Treat 2012, 133:753-757.
20. Korde L.A., Zujewski J.A., Kamin L., Giordano S., Domchek S., Anderson W.F., et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010, 28:2114-2122.
21. Nahleh Z.A., Srikantiah R., Safa M., Jazieh A.R., Muhleman A., Komrokji R. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 2007, 109:1471-1477.